================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): April 12, 2007
SANGAMO BIOSCIENCES, INC.
---------------------------------------------------
(Exact name of registrant specified in its charter)
Delaware 000-30171 68-0359556
---------------------------- ------------ -------------------
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
501 Canal Blvd, Suite A100, Richmond, California 94804
------------------------------------------------ ----------
(Address of principal executive offices) (Zip Code)
Registrant's telephone, including area code: (510) 970-6000
--------------------------------------------------------------
(Former name and former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
ITEM 5.02. DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS;
APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
(e) On April 12, 2007, the Compensation Committee adopted a senior
management bonus plan covering the senior management of the Company, including
the Company's five executive officers: Edward O. Lanphier II, Dale G. Ando,
M.D., David Ichikawa, Philip Gregory, D. Phil., and Greg S. Zante
("Executives"). Under the plan, bonuses of up to 25% of base salary for Messrs.
Ando, Ichikawa, Gregory and Zante and of up to 50% of base salary for Mr.
Lanphier will be awarded by the Compensation Committee to the Executives based
on the Company's achievement of corporate objectives for 2007 and the
performance of each Executive. The 2007 corporate objectives include attaining
certain goals with respect to ongoing clinical trials, initiation of certain new
ZFP Therapeutic Phase 1 clinical trials, consummating certain business
development transactions, defined progress in pre-clinical programs and
technology applications, and cash management. Awards will be based on the
Compensation Committee's judgment of the degree to which the Company achieves
its 2007 corporate objectives and the contribution of each Executive towards the
Company's success.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
SANGAMO BIOSCIENCES, INC.
Date: April 18, 2007 By: /s/ Greg S. Zante
-----------------------
Name: Greg S. Zante
Title: Vice President, Finance
and Administration